L. Pandite

发表

Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.

Tae Min Kim, Bruce E Johnson, Harry J M Groen, 2016, The Lancet. Oncology.

Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover - The Case of Pazopanib in Advanced Renal Cell Carcinoma

T. Delea, R. Motzer, C. Sternberg, 2016, Oncology.

Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors

H. Hurwitz, A. Dowlati, D. Collins, 2005 .

Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors.

H. Hurwitz, A. Dowlati, A. Suttle, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors.

David A. Smith, Suzanne F. Jones, A. Stead, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies.

E. Rowinsky, G. Schwartz, J. D. de Bono, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I, open-label study of lapatinib (GW572016) plus trastuzumab; a clinically active regimen

Suzanne F. Jones, B. Overmoyer, H. Burris, 2005 .

A phase I, open-label study of the safety and pharmacokinetics (PK) of pazopanib (P) and lapatinib (L) administered concurrently.

J. Verweij, H. Hurwitz, A. Suttle, 2006, Journal of Clinical Oncology.

Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma.

Daniel K. Wells, S. Grupp, W. Tap, 2018, Cancer discovery.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Phase I trial to determine the safety and tolerability of GW572016 in combination with oxaliplatin (OX)/5-fluorouracil (5-FU)/leucovorin (LV) [FOLFOX4] in patients with solid tumors.

D. Richel, J. Schellens, J. Beijnen, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of GW572016 (lapatinib), a dual kinase inhibitor, in combination with irinotecan (IR), 5-fluorouracil (FU) and leucovorin (LV)

David A. Smith, D. Kerr, K. Flaherty, 2005 .

Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.

Suzanne F. Jones, B. Overmoyer, H. Burris, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer

E. Rowinsky, L. Goldstein, Q. Chu, 2008, Clinical Cancer Research.

APhase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer

E. Rowinsky, L. Goldstein, Q. Chu, 2008 .

Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients.

N. Kaplowitz, P. Harter, T. Powles, 2015, European journal of cancer.

Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer.

Patricia M. LoRusso, Ronald A. Fleming, Barbara L. Weber, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tolerability and anti-tumor activity of recombinant human IL-18 (rhIL-18) administered as five daily intravenous infusions in patients with solid tumors

J. Mier, M. Robertson, T. Logan, 2004 .

A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients

E. Rowinsky, L. Goldstein, Q. Chu, 2005 .

Clinical activity of GW572016 in EGF10003 in patients with solid tumors.

David A. Smith, A. Stead, G. Wilding, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Open label non-randomized multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259 SPEAR T-cellsTM in HLA-A*02+ patients with synovial sarcoma (NCT01343043)

S. Grupp, C. Mackall, G. Kari, 2016 .

Autologous genetically engineered NY-ESO-1c259T in HLA-A*02:01, HLA*02:05 and HLA*02:06 positive patients with NY-ESO-1 expressing tumors.

G. Linette, S. Grupp, H. Kluger, 2016 .

Cytokine release syndrome (CRS) in patients treated with NY-ESO-1c259 TCR.

K. Odunsi, C. Mackall, G. Kari, 2016 .

Optimizing engineered TCR T cell therapy for synovial sarcoma

B. Jakobsen, W. Tap, C. Mackall, 2015, Journal of Immunotherapy for Cancer.

429 Phase 1 dose escalation study of the agonist redirected checkpoint, SL-172154 (SIRPα-Fc-CD40L) in subjects with platinum-resistant ovarian cancer

F. Rangwala, B. Ma, E. Hamilton, 2021, Journal for ImmunoTherapy of Cancer.

A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors.

A. Stead, G. Wilding, H. Burris, 2004, Journal of Clinical Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.